Treatment of Auricular Hematomas by OK-432: How and Why It Works.


Journal

Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology
ISSN: 1537-4505
Titre abrégé: Otol Neurotol
Pays: United States
ID NLM: 100961504

Informations de publication

Date de publication:
09 2019
Historique:
pubmed: 28 7 2019
medline: 14 5 2020
entrez: 27 7 2019
Statut: ppublish

Résumé

The aim of this article was to investigate the effectiveness and underlying mechanisms of OK-432 therapy in patients with auricular hematomas. Case series with planned data collection. We tried this therapy in 47 patients with auricular hematoma between April 2008 and August 2018. We aspirated as much of the fluid content of each lesion as possible with a 21-gage needle. We injected OK-432 solution into the lesion with the same needle that we used for aspiration. We performed this treatment at an outpatient basis without hospitalization. Disappearance and marked reduction of the lesion were observed in all patients who had this therapy, and local scarring and deformity of the auricle did not occur in any patients. As adverse effects, local pain at the injection site and fever (37-38.5°C) were observed in some cases of the patients who had this therapy. The concentrations of various cytokines in each aspirate before and after OK-432 therapy were investigated. The production of tumor necrosis factor-α, interleukin-6, interleukin-8, interferon gamma, vascular endothelial growth factor, and periostin was significantly elevated in the aspirate fluid after OK-432 therapy. OK-432 therapy is simple, easy, safe, effective, and can be used as a substitute for surgery in the treatment of auricular hematoma.

Identifiants

pubmed: 31348135
doi: 10.1097/MAO.0000000000002336
doi:

Substances chimiques

Picibanil 39325-01-4

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e820-e823

Auteurs

Nobuo Ohta (N)

Division of Otolaryngology, Tohoku Medical and Pharmaceutical University Hospital, Miyaginoku, Sendai.

Shigeru Fukase (S)

Fukase Clinic.
Division of Anatomy and Cell Biology, Tohoku Medical and Pharmaceutical University, Sendai.

Yusuke Kusano (Y)

Division of Otolaryngology, Tohoku Medical and Pharmaceutical University Hospital, Miyaginoku, Sendai.

Yutaro Saito (Y)

Division of Otolaryngology, Tohoku Medical and Pharmaceutical University Hospital, Miyaginoku, Sendai.

Yutaka Tateda (Y)

Division of Otolaryngology, Tohoku Medical and Pharmaceutical University Hospital, Miyaginoku, Sendai.

Yusuke Ishida (Y)

Division of Otolaryngology, Tohoku Medical and Pharmaceutical University Hospital, Miyaginoku, Sendai.

Ryoukichi Ikeda (R)

Division of Otolaryngology, Tohoku Medical and Pharmaceutical University Hospital, Miyaginoku, Sendai.

Muneharu Yamazaki (M)

Division of Otolaryngology, Tohoku Medical and Pharmaceutical University Hospital, Miyaginoku, Sendai.

Junya Ono (J)

Shino-Test Corporation, Sagamihara.

Kenji Izuhara (K)

Division of Medical Biochemistry, Department of Biomolecular Sciences, Saga Medical School, Saga, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH